Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.89 USD | +0.30% | -1.17% | +19.62% |
Financials (USD)
Sales 2024 * | 167M | Sales 2025 * | 301M | Capitalization | 1.53B |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | 91M | EV / Sales 2024 * | 9.55 x |
Net Debt 2024 * | 66.33M | Net cash position 2025 * | 5.71M | EV / Sales 2025 * | 5.07 x |
P/E ratio 2024 * |
-37.4
x | P/E ratio 2025 * |
21.2
x | Employees | 154 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 39.35% |
Latest transcript on Avadel Pharmaceuticals plc
1 day | +0.30% | ||
1 week | -1.17% | ||
Current month | +32.16% | ||
1 month | +34.58% | ||
3 months | +15.76% | ||
6 months | +61.78% | ||
Current year | +19.62% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Thomas McHugh
DFI | Director of Finance/CFO | 59 | 19-12-01 |
Scott Macke
COO | Chief Operating Officer | - | 14-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Ende
BRD | Director/Board Member | 55 | 18-11-30 |
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Mark McCamish
BRD | Director/Board Member | 72 | 19-12-04 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 16.89 | +0.30% | 510,834 |
24-03-27 | 16.84 | +3.69% | 355,913 |
24-03-26 | 16.24 | -2.11% | 463,601 |
24-03-25 | 16.59 | -3.66% | 783,230 |
24-03-22 | 17.22 | +0.76% | 917,945 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.62% | 1.53B | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |